Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors
View/ Open
Issue Date
2019-09-17Author
Sajesh, Babu V.
On, Ngoc H.
Omar, Refaat
Alrushaid, Samaa
Kopec, Brian M.
Wang, Wei-Guang
Sun, Han-Dong
Lillico, Ryan
Lakowski, Ted M.
Siahaan, Teruna J.
Davies, Neal M.
Puno, Pema-Tenzin
Vanan, Magimairajan Issai
Miller, Donald W.
Publisher
MDPI
Type
Article
Article Version
Scholarly/refereed, publisher version
Rights
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
Metadata
Show full item recordAbstract
The blood-brain barrier (BBB) poses a major obstacle by preventing potential therapeutic agents from reaching their intended brain targets at sufficient concentrations. While transient disruption of the BBB has been used to enhance chemotherapeutic efficacy in treating brain tumors, limitations in terms of magnitude and duration of BBB disruption exist. In the present study, the preliminary safety and efficacy profile of HAV6, a peptide that binds to the external domains of cadherin, to transiently open the BBB and improve the delivery of a therapeutic agent, was evaluated in a murine brain tumor model. Transient opening of the BBB in response to HAV6 peptide administration was quantitatively characterized using both a gadolinium magnetic resonance imaging (MRI) contrast agent and adenanthin (Ade), the intended therapeutic agent. The effects of HAV6 peptide on BBB integrity and the efficacy of concurrent administration of HAV6 peptide and the small molecule inhibitor, Ade, in the growth and progression of an orthotopic medulloblastoma mouse model using human D425 tumor cells was examined. Systemic administration of HAV6 peptide caused transient, reversible disruption of BBB in mice. Increases in BBB permeability produced by HAV6 were rapid in onset and observed in all regions of the brain examined. Concurrent administration of HAV6 peptide with Ade, a BBB impermeable inhibitor of Peroxiredoxin-1, caused reduced tumor growth and increased survival in mice bearing medulloblastoma. The rapid onset and transient nature of the BBB modulation produced with the HAV6 peptide along with its uniform disruption and biocompatibility is well-suited for CNS drug delivery applications, especially in the treatment of brain tumors.
Description
This work is licensed under a Creative Commons Attribution 4.0 International License.
Collections
Citation
Sajesh, B. V., On, N. H., Omar, R., Alrushaid, S., Kopec, B. M., Wang, W. G., Sun, H. D., Lillico, R., Lakowski, T. M., Siahaan, T. J., Davies, N. M., Puno, P. T., Vanan, M. I., & Miller, D. W. (2019). Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors. Pharmaceutics, 11(9), 481. https://doi.org/10.3390/pharmaceutics11090481
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.